Article Details
Retrieved on: 2024-12-23 14:52:57
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Truist Securities maintained a Hold rating on AnaptysBio shares, reducing the price target from $30 to $20, following the recent Phase 2b trial ...
Article found on: www.investing.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here